Retraction Note to: Bismuth adjuvant ameliorates adverse effects of high-dose chemotherapy in patients with multiple mye
- PDF / 139,730 Bytes
- 2 Pages / 595.276 x 790.866 pts Page_size
- 42 Downloads / 141 Views
RETRACTION NOTE
Retraction Note to: Bismuth adjuvant ameliorates adverse effects of high-dose chemotherapy in patients with multiple myeloma and malignant lymphoma undergoing autologous stem cell transplantation: a randomised, double-blind, prospective pilot study Per Boye Hansen 1,2 & Milena Penkowa 3
# Springer-Verlag GmbH Germany, part of Springer Nature 2020
Retraction Note to: Support Care Cancer (2017) 25:1279–1289 https://doi.org/10.1007/s00520-016-3522-6 The Editor-in-Chief has retracted this article [1]. Following publication, concerns were raised with respect to data and data analyses present in the article. Some of the concerns were voiced in a Letter to Editor [2] and subsequently further concerns were received by the journal. Upon post-publication review of the raw data provided by the authors, the reviewer was unable to replicate the findings and conclusions of the article. The Editor-in-Chief and the article’s original Handling Editor agreed that the data reported in this article are therefore unreliable and retraction of the article is appropriate. A summary of the re-analyses of the data can be found below.
were multiple myeloma (n = 26) and lymphoma (n = 24). The toxicities of interest consisted of stomatitis, infection, diarrhea, febrile neutropenia (FN) and cytopenia. The investigators concluded that in patients with bismuth prophylaxis, there was a reduced incidence and duration of grade 2 stomatitis, infections, duration of cytopenia and the incidence of FN. In patients with lymphoma, bismuth significantly reduced the duration of diarrhea. Gender related differences were also reported in myeloma patients with respect to the severity of stomatitis, the incidence of febrile neutropenia, infection as well as the duration of cytopenia. Gender related differences were also reported in the incidence of stomatitis in lymphoma patients.
The authors do not agree to this retraction. Background The study by Hansen et al., was a small randomized trial comparing bismuth to placebo tablets for the prevention of toxicity in hematological patients receiving chemotherapy (final reported n = 50). The two subgroups of patients enrolled The online version of the original article can be found at https://doi.org/ 10.1007/s00520-016-3522-6 * Per Boye Hansen [email protected] 1
Department of Hematology, Herlev Hospital, University of Copenhagen, 2720 Herlev, Denmark
2
Department of Hematology, University Hospital of Roskilde, DK-4000 Roskilde, Denmark
3
Section for Neuroprotection, Hjerneeksperten, 1718 Copenhagen, Denmark
Data Reanalysis The Journal contacted the authors of the paper to request the original data; the authors complied and provided electronic copies and print copies where now electronic version was available. An independent biostatistician was asked to assess the article and the data provided, and to consider the following: & & &
The appropriateness of the analytical approach used by the authors, and presented in the article. To analyze the data using the authors’ approach to see if,
Data Loading...
